Peregrine Capital Management LLC Purchases New Stake in CeriBell, Inc. $CBLL

Peregrine Capital Management LLC purchased a new stake in CeriBell, Inc. (NASDAQ:CBLL) during the second quarter, HoldingsChannel reports. The firm purchased 341,659 shares of the company’s stock, valued at approximately $6,399,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of CeriBell during the first quarter worth $36,000. New York State Common Retirement Fund acquired a new stake in shares of CeriBell during the first quarter worth $67,000. Quantbot Technologies LP acquired a new stake in shares of CeriBell during the first quarter worth $175,000. Rhumbline Advisers lifted its holdings in shares of CeriBell by 26.5% during the first quarter. Rhumbline Advisers now owns 15,629 shares of the company’s stock worth $300,000 after buying an additional 3,276 shares in the last quarter. Finally, Nuveen LLC acquired a new stake in shares of CeriBell during the first quarter worth $311,000.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CBLL. Raymond James Financial began coverage on CeriBell in a report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell currently has an average rating of “Moderate Buy” and a consensus price target of $30.50.

CeriBell Price Performance

Shares of NASDAQ CBLL opened at $12.89 on Tuesday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 12.91 and a current ratio of 13.31. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $32.75. The stock has a market capitalization of $472.60 million and a P/E ratio of -4.31. The stock’s fifty day moving average is $12.07 and its 200 day moving average is $14.73.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. CeriBell had a negative return on equity of 48.42% and a negative net margin of 63.83%.The company had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.52 million. CeriBell has set its FY 2025 guidance at EPS. Sell-side analysts forecast that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CTO Raymond Woo sold 11,112 shares of the firm’s stock in a transaction dated Friday, October 3rd. The stock was sold at an average price of $12.54, for a total value of $139,344.48. Following the sale, the chief technology officer directly owned 167,704 shares of the company’s stock, valued at $2,103,008.16. This trade represents a 6.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 20.10% of the stock is owned by company insiders.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.